Sensyne Health plc Provided revenue guidance for fiscal year 2021. The Company's Discovery Sciences operations are currently performing strongly, and accordingly the Directors expect this division to contribute a significant proportion of the total revenues for the year ending 30 April 2021. This represents a change to the expected revenue mix at the beginning of fiscal year 2021, due to the delays the pandemic has caused to the launch of software products in the US and the Company's strategic decision to make its software free to use by the NHS for a 12-month period.